Literature DB >> 21053841

Pilot study of a nonpharmacological intervention for delirium superimposed on dementia.

Ann M Kolanowski1, Donna M Fick, Linda Clare, Melinda Steis, Malaz Boustani, Mark Litaker.   

Abstract

Delirium is a common neuropsychiatric syndrome that occurs most frequently in older adults with dementia and is referred to as delirium superimposed on dementia (DSD). Our aim in this pilot project was to demonstrate that implementation of cognitively stimulating activities is clinically feasible and has potential to reduce delirium severity and duration and functional loss in post-acute care settings. We randomized newly admitted participants with DSD to treatment (n = 11) and control (n = 5) conditions and conducted daily blinded assessments of delirium, delirium severity, and functional status for up to 30 days. The control group had a significantly greater decrease in physical function and mental status over time compared with the intervention group. Delirium, severity of delirium, and attention approached significance, and improvement over time favored the intervention group. Although not statistically significant, a difference in mean (7.0 versus 3.27) and median (7.0 versus 3.0) days with delirium was found, with the control group having more days of delirium. Copyright 2011, SLACK Incorporated.

Entities:  

Mesh:

Year:  2010        PMID: 21053841     DOI: 10.3928/19404921-20101001-98

Source DB:  PubMed          Journal:  Res Gerontol Nurs        ISSN: 1938-2464            Impact factor:   1.571


  9 in total

Review 1.  Gender differences in factors associated with delirium severity in older adults with dementia.

Authors:  Ann M Kolanowski; Nikki L Hill; Esra Kurum; Donna M Fick; Andrea M Yevchak; Paula Mulhall; Linda Clare; Michael Valenzuela
Journal:  Arch Psychiatr Nurs       Date:  2014-02-05       Impact factor: 2.218

2.  Feasibility and Utility of Online Dementia Care Training for Hospital Staff: The CARES® Dementia-Friendly Hospital Program.

Authors:  John V Hobday; Joseph E Gaugler; Mary S Mittelman
Journal:  Res Gerontol Nurs       Date:  2017-02-02       Impact factor: 1.571

3.  Personality as a moderator of cognitive stimulation in older adults at high risk for cognitive decline.

Authors:  Nikki L Hill; Ann M Kolanowski; Donna Fick; Vernon M Chinchilli; Rita A Jablonski
Journal:  Res Gerontol Nurs       Date:  2014-03-18       Impact factor: 1.571

4.  Practical Protocol for Implementing Cognitive Stimulation in Persons with Delirium Superimposed on Dementia.

Authors:  Ann M Kolanowski; Nikki Hill; Linda Clare; Patricia Marx
Journal:  Nonpharmacol Ther Dement       Date:  2012

5.  Effect of Cognitively Stimulating Activities on Symptom Management of Delirium Superimposed on Dementia: A Randomized Controlled Trial.

Authors:  Ann Kolanowski; Donna Fick; Mark Litaker; Paula Mulhall; Linda Clare; Nikki Hill; Jacqueline Mogle; Malaz Boustani; David Gill; Andrea Yevchak-Sillner
Journal:  J Am Geriatr Soc       Date:  2016-11-12       Impact factor: 5.562

6.  The American Geriatrics Society/National Institute on Aging Bedside-to-Bench Conference: Research Agenda on Delirium in Older Adults.

Authors: 
Journal:  J Am Geriatr Soc       Date:  2015-03-31       Impact factor: 5.562

7.  Study protocol for the recreational stimulation for elders as a vehicle to resolve delirium superimposed on dementia (Reserve For DSD) trial.

Authors:  Ann M Kolanowski; Donna M Fick; Mark S Litaker; Linda Clare; Doug Leslie; Malaz Boustani
Journal:  Trials       Date:  2011-05-11       Impact factor: 2.279

8.  A clinical update on delirium: from early recognition to effective management.

Authors:  Joaquim Cerejeira; Elizabeta B Mukaetova-Ladinska
Journal:  Nurs Res Pract       Date:  2011-06-16

9.  Cognitive Stimulation as a Therapeutic Modality for Dementia: A Meta-Analysis.

Authors:  Kayoung Kim; Ji Won Han; Yoonseop So; Jiyeong Seo; You Joung Kim; Joon Hyuk Park; Seok Bum Lee; Jung Jae Lee; Hyun-Ghang Jeong; Tae Hui Kim; Ki Woong Kim
Journal:  Psychiatry Investig       Date:  2017-09-11       Impact factor: 2.505

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.